Atlas Trials

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

Clinical trial NCT06784791 · RECRUITING

Trial details

NCT number
NCT06784791
Sponsor
University Hospital, Essen
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Cancer (NSCLC)
Start date
2024-11-06
Primary completion
2027-07-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.